Letrozol Bluefish 2,5 mg

Description

Indications for use

• Adjuvant therapy of breast cancer in postmenopausal women with hormone positive early stage breast cancer.
• Continuation of adjuvant therapy in postmenopausal women with hormone positive early stage breast cancer who have previously received standard adjuvant treatment with tamoxifen.
• Advanced breast cancer in postmenopausal women (natural or induced) who have previously received anti-estrogen therapy, following relapse or progression of disease
• as first-line therapy in early-stage hormone-dependent breast cancer in postmenopausal women
  neoadjuvant therapy for localised estrogen receptor-positive breast cancer in postmenopausal women followed by organ-sparing surgery in cases
• where such surgery was not initially considered indicated. After surgery, a decision should be made on the continued use of Letroz, taking into account generally accepted treatment regimens

Method of administration and dosage

Adults. The recommended dose of Letroz is 2.5 mg once daily. For prolonged adjuvant treatment, the duration of treatment with Letroz is up to 5 years under the supervision of the treating oncologist or throughout the period of disease progression.

Patients with hepatic and/or renal impairment. No dose adjustment is required in patients with moderate to moderately severe hepatic impairment or renal impairment (with creatinine clearance ³ 10 ml/min). However, in severe hepatic insufficiency, the recommended dose of Letroz is 2.5 mg once daily every other day.